News
As of May 22, manufacturers are no longer allowed to distribute the compounded versions of semaglutide, which Novo Nordisk sells under the brand Wegovy for weight loss and Ozempic for diabetes.
The 50-year-old is now on Novo Nordisk ’s Wegovy, but worries because it is less effective. Studies have shown Wegovy helps people lose less weight, on average, than Zepbound.
Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users. New Africa – stock.adobe.com Participants, none of whom are diabetic ...
Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.
Campbell gained access to Wegovy through South Carolina Medicaid's decision in late 2024 to cover these weight loss drugs. But the medications remain out of reach for millions of patients across ...
In a head-to-head study in the New England Journal of Medicine, people taking Zepbound, Wegovy, Zepbound led to greater weight loss.
Wegovy can cost upward of $349 for a 2.5-milligram vial. Meanwhile, Noom’s compounded semaglutide, offered through a telehealth model, allows patients to access the treatment at a fraction of ...
Updated on: May 12, 2025 / 12:39 PM EDT / CBS News ...
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback